SCHEMBL17586457

SCHEMBL17586457

CN1CCC2(C1)OC(=O)c1ccc(Br)cc12

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 2/20 0.44
AVPR1A P37288 6/20 0.42
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
SIGMAR1 Q99720 3/20 0.39
CTSC P53634 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HSD11B1 P28845 4/20 0.37
CYP2D6 P10635 1/20 0.37
DRD2 P14416 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17586460 0.92 AVPR1A (0.48) NPY5RAVPR1AOPRM1OPRD1SIGMAR1
SCHEMBL17586456 0.89 OPRM1 (0.40) NPY5RAVPR1AOPRM1OPRD1CTSC
SCHEMBL17001260 0.81 SIGMAR1 (0.56) NPY5RAVPR1ASIGMAR1HSD11B1CYP2D6
SCHEMBL3839594 0.81 AVPR1A (0.60) NPY5RAVPR1ASIGMAR1DRD2
SCHEMBL17586449 0.77 USP30 (0.42) HSD11B1CYP2D6
SCHEMBL25866294 0.75 OPRM1 (0.43) NPY5RAVPR1AOPRM1OPRD1SIGMAR1
SCHEMBL14349529 0.75 AVPR1A (0.60) AVPR1AOPRM1OPRD1SIGMAR1DRD2
SCHEMBL4367569 0.75 AVPR1A (0.48) NPY5RAVPR1ASIGMAR1DRD2
SCHEMBL18373156 0.74 NPY5R (0.45) NPY5RAVPR1AOPRM1OPRD1SIGMAR1
SCHEMBL18373219 0.74 OPRM1 (0.42) NPY5RAVPR1AOPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023134656-A1 PEPTIDYL NITRILE COMPOUND AND USE THEREOF 上海壹典医药科技开发有限公司 2023-07-20 WO disclosed
US-RE47636-E1 Substituted spirocycles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-10-08 US disclosed
EP-3191487-B1 SPIROCYCLIC INHIBITORS OF CATHEPSIN C BOEHRINGER INGELHEIM INT (DE) 2019-08-07 EP disclosed
EP-3511331-A1 SPIROCYCLIC INHIBITORS OF CATHEPSIN C Boehringer Ingelheim International GmbH (DE) 2019-07-17 EP disclosed
US-9879026-B2 Substituted spirocycles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-01-30 US disclosed
US-9879026-B2 Substituted spirocycles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-01-30 US disclosed
US-20170073352-A1 NOVEL SUBSTITUTED SPIROCYCLES BOEHRINGER INGELHEIM INT (DE) 2017-03-16 US disclosed
US-20170073352-A1 NOVEL SUBSTITUTED SPIROCYCLES BOEHRINGER INGELHEIM INT (DE) 2017-03-16 US disclosed
US-9540373-B2 Substituted spirocycles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-01-10 US disclosed
US-9540373-B2 Substituted spirocycles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-01-10 US disclosed
US-20160075704-A1 NOVEL SUBSTITUTED SPIROCYCLES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160075704-A1 NOVEL SUBSTITUTED SPIROCYCLES CTSC, CTSE, CTSS NPY5R 2143/4885AVPR1A 1627/4885OPRM1 2695/4885
US-20170073352-A1 NOVEL SUBSTITUTED SPIROCYCLES CTSC, CTSE, CTSS NPY5R 2143/4885AVPR1A 1627/4885OPRM1 2695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.